| Project/Area Number |
24592014
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Kansai Medical University |
|---|
Principal Investigator |
KON Masanori 関西医科大学, 医学部, 教授 (70225605)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAIBORI Masaki 関西医科大学, 医学部, 准教授 (30333199)
FUJISAWA Junichi 関西医科大学, 医学部, 教授 (40181341)
TODO Tomoki 東京大学, 医科学研究所, 教授 (80272566)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 増殖型遺伝子組換えウィルス / 単純ヘルペス英ルス / 抗腫瘍免疫 / 肝臓がん / 単純ヘルペスウィルス / 増殖型遺伝子組換えウイル / 単純ヘルペスウイル / 増殖型遺伝子組換えウイルス / 単純ヘルペスウイルス / 肝細胞がん |
|---|
| Outline of Final Research Achievements |
The use of recombinant viruses which kill tumor cells selectively in the course of viral replication is called an oncolytic virus therapy. G47Δ is a third-generation oncolytic herpes simplex virus type 1 (HSV-1) that has triple genetic modifications in the viral genome, and has already been used in clinical studies. Deletions in the γ34.5 gene and inactivation of the ICP6 gene make the virus replicate efficiently and selectively in tumor cells, and the deletion in α47 gene efficiently induces tumor cell specific immune responses. T-01 has a similar genetic structure to G47Δ. Antitumor effect of T-01 was evaluated in this study using HCC cell lines. In cytotoxicity assays in vitro, all 11 HCC cell lines tested were susceptible to T-01. T-01 was tested in vivo using 4 HCC cell lines in subcutaneous and orthotopic tumor models in nude mice. In both models, intratumoral inoculation of T-01 inhibited tumor growth efficiently compared with mock inoculation.
|
